Aug. 11 at 12:26 PM
$BOLT The mayor weaknesses of first Gen ISACs were tolerability and efficacy. BOLTs BDC-1001 did much better than all other ISACs, both in safety and efficacy. In the RP2D cohort they had encouraging efficacy compared to their competition, where only Silverbacks ISAC got a PR out of 14 patients or so. They showed that BDC-1001 only worked in high antigen density cancers, where ADCs "shine". anti-claudin ADC Vyloy + Chemo improved OS and PFS, but ORR was basically similar to that of chemo+placebo. Preclinical data for BDC-4182 shows mayor improvements in efficacy. It might be the case that their 2nd gen ISAC is able to bind antigen even in low antigen density tumors. That would increase ORR a lot. However, we dont know if the gain in efficacy will make safety worse. Noone knows if they got it with the 2nd gen, and market does not believe in their pre-clinical stuff being reliable, but a small chance exists. Either lose 90% of your money or make 2-3000%. I bought a few yesterday
